Effects of exogenous urotensin II on vascular remodelling after balloon injury

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 4, 2010, Pages 477-481

  Zhang, Li Fang ^a,b   Ding, Wen Hui ^a   Shi, Li Bin ^a   Li, Kang ^a   Haom, Yan Jie ^a   Ke, Yuan Nan ^b   Tang, Zhao Shu ^c  

^a PEKING UNIVERSITY   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Arteries; Balloon angioplasty; Extracellular matrix; Restenosis; Urotensin II; Vascular remodelling

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLINE; HYDROXYPROLINE; INTERSTITIAL COLLAGENASE; MESSENGER RNA; NEUROTENSIN RECEPTOR; PROLINE; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA STENOSIS; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; IMMUNOREACTIVITY; IN VITRO STUDY; MALE; MORPHOMETRICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN EXPRESSION; RAT; THORACIC AORTA; UPREGULATION;

ANGIOPLASTY, BALLOON; ANIMALS; AORTA, THORACIC; AORTIC DISEASES; AORTIC STENOSIS, SUBVALVULAR; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; HYPERPLASIA; MALE; MATRIX METALLOPROTEINASE 1; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TIME FACTORS; TUNICA INTIMA; UP-REGULATION; UROTENSINS;

EID: 77949876908     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05336.x     Document Type: Article

References (33)

1. Shi LB, Ding WH, Li DY et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 2006 188 : 260 264.
2. Yoshimoto T, Matsushita M, Hirata Y. Role of urotensin II in peripheral tissue as an autocrine/paracrine growth factor. Peptides 2004 25 : 1775 1781.
3. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J. Hypertens. 2001 19 : 2191 2196.
4. Tzanidis A, Hannan RD, Thomas WG et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res. 2003 93 : 246 253.
5. Zhang YG, Li YG, Liu BG et al. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol. Sin. 2007 28 : 36 43.
6. Wang H, Mehta JL, Chen K, Zhang X, Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J. Cardiovasc. Pharmacol. 2004 44 : 577 581.
7. Zou Y, Nagai R, Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. 2001 508 : 57 60.
8. Rakowski E, Hassan GS, Dhanak D, Ohlstein EH, Douglas SA, Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J. Mol. Cell. Cardiol. 2005 39 : 785 791.
9. Bousette N, Patel L, Douglas SA, Ohlstein EH, Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 2004 176 : 117 123.
10. Suguro T, Watanabe T, Ban Y et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am. J. Hypertens. 2007 20 : 211 217.
11. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J. Hypertens. 2004 22 : 1341 1344.
12. Heringlake M, Kox T, Uzun O et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul. Pept. 2004 121 : 129 136.
13. Lapp H, Boerrigter G, Costello-Boerrigter LC et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int. J. Cardiol. 2004 94 : 93 7.
14. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers. Peptides 2006 27 : 1527 1531.
15. Totsune K, Takahashi K, Arihara Z et al. Role of urotensin II in patients on dialysis. Lancet 2001 358 : 810 811.
16. Coulouarn Y, Lihrmann I, Jegou S et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci U S A 1998 95 (26 15803 15808.
17. Ames RS, Sarau HM, Chambers JK et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999 401 (6750 282 286.
18. Matsushita M, Shichiri M, Imai T et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 2001 19 (12 2185 2190.
19. Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and rat arterial wall. Circ. Res. 1991 68 : 450 456.
20. Kompa AR, Thomas WG, See F, Tzanidis A, Hannan RD, Krum H. Cardiovascular role of urotensin II. Effect of chronic infusion in the rat. Peptides 2004 25 : 1783 1788.
21. Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, Schafer AI. Adenovirus-mediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 2001 104 : 2710 2715.
22. Strauss BH, Chisholm RJ, Keeley FW, Gotlieb AI, Logan RA, Armstrong PW. Extracellular matrix remodeling after balloon angioplas injury in a rabbit model of restenosis. Circ. Res. 1994 75 : 650 658.
23. Huang HC, Ma CY, Yang M, Tang CS, Wang HY. Adrenomedullin impairs the profibrotic effects of transforming growth factor-beta1 through recruiting Smad6 protein in human renal tubular cells. Cell Physiol. Biochem. 2005 15 : 117 124.
24. Russell FD. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol. Ther. 2004 103 : 223 243.
25. Yang JJ, Lin WH, Zhang YG et al. Study on the changes of plasma urotensin II level in coronary atherosclerosis and coronary heart disease after angioplasty. Chin. J. Geriatr Cardiovasc. Cerebrovasc. Dis. 2001 3 : 373 375 (in Chinese).
26. Xia CF, Xu SP, Zhang YG et al. The alteration of urotensin-II receptors in rat aorta after balloon angioplasty injury. Chin. J. Pathophysiol. 2001 17 : 593 597 (in Chinese).
27. Shi Y, O'Brien JE, Fard A, Mannion JD, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation 1996 94 : 1655 1664.
28. Lin L, Ding WH, Jiang W et al. Urotensin-II activates l-arginine/nitric oxide pathway in isolated rat aortic adventitia. Peptides 2004 25 : 1977 1984.
29. Zhang YG, Li J, Li YG, Wei RH. Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta. J. Hypertens. 2008 26 : 1119 1126.
30. Indolfi C, Mongiardo A, Curcio A, Torella D. Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc. Med. 2003 13 : 142 148.
31. Wong L, Cheung B, Li YY, Tang F. Expressions of urotensin II and urotensin II receptor are up-regulated in cardiovascular tissues in experimentally induced endotoxaemia. Am. J. Hypertens. 2005 18 : A125.
32. Bousette N, Chouiali L, Ohlstein E, Douglas SA, Giaid A. Urotensin-II immunoreactivity in normolipidemic and hyperlipidemic New Zealand white rabbits following balloon angioplasty and stenting. Int. J. Biomed. Sci. 2007 3 : 38 45.
33. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. 2003 104 : 1 5.